Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center

Study of GBR 1342, a CD38 / CD3 Bispecific Antibody, in Subjects With Previously Treated Multiple Myeloma

Multiple Myeloma

The purpose of this study is to determine the safety profile and maximum tolerable dose (MTD) of single-agent GBR 1342 in subjects with multiple myeloma who have received prior therapies.
Multiple Myeloma
Cornell, Robert

Phase 1 Study Of PF-06863135, A BCMA- CD3 Bispecific Ab, In Relapse / Refractory Multiple Myeloma

To assess the safety and tolerability at increasing dose levels of PF-06863135 in patients with relapse / refractory multiple myeloma in order to determine the maximum tolerated dose and select the recommended Phase 2 dose.
Not Available
Cornell, Robert

To learn more about any of our clinical
trials, call 1-800-811-8480 or complete
the online Self-Referral Form here: